A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
← catalyst calendarNCT04482309 · readout in 216 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Daiichi Sankyo Co., Ltd..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
477actual
Sites
89
Countries
Australia, Belgium, Brazil +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-18 | actual | When the study began enrolling |
| Primary completion | 2027-03-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-23 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
- Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Intervention
- Drug: Trastuzumab deruxtecan — also filed as DS-8201a, T-DXd
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured An average of approximately 6 months
Publications
- PMID 42135959 — linked by the registry
- PMID 39261417 — linked by the registry
- PMID 37870536 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed